Non-specific immunotherapy of HIV-1 infection: potential use of the synthetic immunodulator murabutide.
Bahr
George M
GM
Laboratory of Molecular Immunology of Infection and Inflammation, Institut Pasteur de Lille, 1 rue du Professeur Calmette, BP 245, 59019 Lille cedex, France. georges.bahr@pasteur-lille.fr
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use*; D000276:Adjuvants, Immunologic / Q000138:chemical synthesis / Q000627:therapeutic use*; D000818:Animals; D019380:Anti-HIV Agents / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D015497:HIV-1 / Q000187:drug effects* / Q000276:immunology; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects / Q000276:immunology; D007167:Immunotherapy / Q000379:methods
D000276:Adjuvants, Immunologic; D019380:Anti-HIV Agents; D000119:Acetylmuramyl-Alanyl-Isoglutamine; C033575:murabutide